ADMA: constructive FDA pre-IND info on pneumococcal hyperimmune globulin, eyes shorter Ph 3, IND filing

 

ADMA Biologics gets constructive FDA pre-IND feedback for SG-001 pneumococcal hyperimmune globulin, eyes abbreviated registrational Phase 3 and IND filing

• Q3 2026 revenue was $141.1M, beating estimates and rising 5% year over year.
• Q3 2026 GAAP profit equaled $49.9M, or $0.22 per share.
• Company reiterates at least $530M FY2026 revenue guidance, confirming its previously communicated full-year sales outlook.
• Raises minimum FY2026 adjusted net income outlook to $180M and minimum adjusted EBITDA outlook to $275M.

https://finviz.com/stock?t=ADMA&p=d